Company Information

Agenus is an immuno-oncology company focused on the discovery and development of revolutionary new treatments that engage the body’s immune system to benefit patients suffering from cancer. By combining multiple powerful platforms, Agenus has established a highly integrated approach for the discovery, development and manufacture of monoclonal antibodies that modulate targets of interest. In addition, the Company’s cancer vaccine program includes three proprietary platforms focused on individualized and off-the-shelf vaccines uniquely designed for each patient. Agenus’ broad portfolio of novel checkpoint and other immuno-modulatory monoclonal antibodies, vaccines and adjuvants, work in combination to provide the opportunity to create best-in-class therapeutic regimens. The Company has formed collaborations with Merck and Incyte to discover and develop multiple checkpoint antibodies.

 

Press Releases
Jul 16, 2018

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with clinical stage checkpoint antibodies, a pipeline of IND ready antibodies and bispecifics, cancer vaccines, and adoptive cell therapies1,...

Jun 20, 2018

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies1 invites investors and the general public to...

Jun 12, 2018

A study published in Cancer Cell reports on a novel discovery made by Agenus Inc. (NASDAQ: AGEN) that may enhance the immune activity of cancer fighting antibodies, including those targeting...

VIEW ALL PRESS RELEASES

Stock Chart
NASDAQAGEN
Events and Presentations
Monday, July 16, 2018

News Brief

Saturday, July 14, 2018
11:39am EDT

Forward-Looking Statements: This news brief contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding...

Wednesday, June 20, 2018
5:00pm - 6:00pm EDT

“the